GlassScriptPhysician profile
Katherine Castillo
NPI 1952017857
$5,236.18
in general payments reported to CMS, 2019-2025
27 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,170 · 2024: $2,142 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,236.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $883.88 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $848.32 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $837.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $442.56 | 2023-2025 | |
| Corcept Therapeutics | $264.35 | 2025 | Korlym |
| Exact Sciences Corporation | $256.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $193.22 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.97 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $145.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $143.79 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $141.37 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $121.50 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Ardelyx, INC. | $118.23 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.85 | 2023-2025 | Xifaxan |
| Philips North America LLC | $96.80 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Disposable Vest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $86.61 | 2023-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $78.11 | 2024-2025 | |
| Seqirus USA INC | $60.30 | 2024-2025 | Flucelvax, Fluad |
| Paratek Pharmaceuticals, INC. | $41.00 | 2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $35.64 | 2023 | Quviviq |
| Phadia US INC. | $33.37 | 2023-2025 | Immunocap |
| Ibsa Pharma INC. | $30.30 | 2023 | Tirosint, Licart |
| Viatris Specialty LLC | $24.35 | 2025 | Yupelri |
| Boston Scientific Corporation | $22.47 | 2025 | Accolade Sr |
| Sanofi Pasteur INC. | $22.25 | 2023 | |
| Radius Health, INC. | $17.86 | 2025 | Tymlos |
| Theracosbio, LLC | $14.46 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.